Search This Blog

Tuesday, August 6, 2019

Halozyme Therapeutics EPS beats by $0.05, misses on revenue

Halozyme Therapeutics (NASDAQ:HALO): Q2 GAAP EPS of -$0.10 beats by $0.05.
Revenue of $39.15M (+11.2% Y/Y) misses by $3.79M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)